Mechanisms of Therapeutic Resistance in Prostate Cancer
Congressional District Code:
Biomedical Laboratory R&D
April 2018 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
Background: Enhancer of zeste homolog 2 (EZH2) is a component of Polycomb Repressive Complex 2 (PRC2) and a key epigenetic regulator. EZH2 is overexpressed in metastatic prostate cancer (PCa), and its activity is critical for PCa progression and therapeutic resistance. Inhibition of EZH2 has become a promising cancer treatment option. Studies showed that agents depleting EZH2 protein had better antitumor efficacy than those only inhibiting its methyltransferase activity, suggesting that combinat...